Agilon Health (AGL) Financials

$59.96 +32.11 (+115.30%)

As of 12:46 PM Eastern

Annual Income Statements for Agilon Health

This table shows Agilon Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-283	-60	-406	-107	-263	-260	-391
Consolidated Net Income / (Loss)	-283	-60	-407	-107	-263	-260	-391
Net Income / (Loss) Continuing Operations	-114	-63	-384	-92	-195	-250	-405
Total Pre-Tax Income	-115	-62	-383	-91	-194	-249	-404
Total Operating Income	-107	-57	-372	-105	-232	-292	-463
Total Gross Profit	794	1,218	66	111	4,316	6,061	-160
Total Revenue	794	1,218	1,521	2,388	4,316	6,061	5,933
Operating Revenue	794	1,218	1,521	2,388	4,316	6,061	5,933
Total Cost of Revenue	0.00	0.00	1,456	2,277	0.00	0.00	6,093
Operating Cost of Revenue	-	-	1,456	2,277	-	-	6,093
Total Operating Expenses	901	1,275	438	217	4,548	6,353	303
Selling, General & Admin Expense	123	137	428	208	286	269	239
Depreciation Expense	12	14	10	8.95	16	24	29
Impairment Charge	-	-	-	0.00	0.00	3.60	36
Total Other Income / (Expense), net	-8.11	-5.67	-11	15	38	43	59
Interest Expense	9.07	8.14	6.15	4.48	6.66	6.18	6.64
Interest & Investment Income	-	0.00	-6.77	11	16	15	-1.84
Other Income / (Expense), net	0.96	2.47	2.18	8.47	28	34	68
Income Tax Expense	-0.23	0.87	0.89	1.64	0.79	1.45	1.25
Net Income / (Loss) Discontinued Operations	-168	3.16	-23	-15	-68	-9.82	14
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.15	0.00	-0.30	-0.31	-0.21	0.05	0.00
Weighted Average Basic Shares Outstanding	294.74M	323.46M	372.93M	408.15M	408.92M	410.97M	413.97M
Weighted Average Diluted Shares Outstanding	294.74M	323.46M	372.93M	408.15M	408.92M	410.97M	413.97M
Weighted Average Basic & Diluted Shares Outstanding	294.74M	323.46M	372.93M	413.12M	409.54M	412.30M	414.87M

This table shows Agilon Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-31	-230	-6.06	-31	-118	-106	12	-104	-110	-189	49
Consolidated Net Income / (Loss)	-31	-230	-6.03	-31	-118	-106	12	-104	-110	-189	49
Net Income / (Loss) Continuing Operations	-22	-167	3.25	-31	-116	-106	-1.89	-104	-110	-189	30
Total Pre-Tax Income	-21	-167	3.11	-30	-117	-105	-1.69	-104	-111	-188	30
Total Operating Income	-39	-164	-7.18	-43	-134	-108	-22	-116	-131	-194	4.00
Total Gross Profit	37	3,171	75	32	1,451	-1,568	1,533	-52	1,435	-1,594	65
Total Revenue	1,137	1,056	1,604	1,483	1,451	1,522	1,533	1,395	1,435	1,569	1,420
Operating Revenue	1,137	1,056	1,604	1,483	1,451	1,522	1,533	1,395	1,435	1,569	1,420
Total Cost of Revenue	1,100	-2,115	1,529	1,451	0.00	3,090	0.00	1,447	0.00	3,163	1,355
Operating Cost of Revenue	1,100	-	1,529	1,451	-	-	-	1,447	-	-	1,355
Total Operating Expenses	76	3,335	82	76	1,584	-1,459	1,555	64	1,567	-1,400	61
Selling, General & Admin Expense	72	65	76	70	63	60	66	56	56	60	54
Depreciation Expense	4.08	4.74	5.84	5.91	6.22	6.49	6.88	7.32	7.43	6.97	6.79
Total Other Income / (Expense), net	18	-2.57	10	13	16	3.43	20	12	21	6.27	26
Interest Expense	1.62	1.99	1.28	1.70	1.62	1.57	1.52	1.57	1.84	1.72	1.81
Interest & Investment Income	15	-8.02	5.68	9.96	2.05	-2.69	13	5.41	13	-33	12
Other Income / (Expense), net	5.42	7.44	5.89	4.84	16	7.70	9.26	7.88	9.44	41	16
Income Tax Expense	1.21	0.27	-0.13	0.42	-0.59	1.76	0.20	0.06	-0.33	1.32	0.03
Net Income / (Loss) Discontinued Operations	-9.44	-63	-9.28	0.00	-1.18	0.64	14	0.00	0.00	-	19
Basic Earnings per Share	-	-	-	-	-	-	$0.73	-	-	-	$2.95
Weighted Average Basic Shares Outstanding	405.79M	408.92M	408.94M	411.27M	411.59M	410.97M	16.52M	413.84M	414.47M	413.97M	16.60M
Diluted Earnings per Share	-	-	-	-	-	-	$0.73	-	-	-	$2.94
Weighted Average Diluted Shares Outstanding	405.79M	408.92M	408.94M	411.27M	411.59M	410.97M	16.52M	413.84M	414.47M	413.97M	16.66M
Weighted Average Basic & Diluted Shares Outstanding	406.04M	409.54M	411.26M	411.48M	412.02M	412.30M	413.95M	414.42M	414.58M	414.87M	16.68M

This table details how cash moves in and out of Agilon Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	67	-6.52	916	-547	-393	80	-20
Net Cash From Operating Activities	-104	-53	-148	-131	-156	-58	-106
Net Cash From Continuing Operating Activities	-104	-12	-148	-131	-156	-58	-106
Net Income / (Loss) Continuing Operations	-283	-60	-407	-107	-263	-260	-391
Consolidated Net Income / (Loss)	-283	-60	-407	-107	-263	-260	-391
Depreciation Expense	41	14	15	14	20	24	29
Non-Cash Adjustments To Reconcile Net Income	120	30	302	21	97	47	68
Changes in Operating Assets and Liabilities, net	17	3.66	-58	-59	-10	131	189
Net Cash From Investing Activities	-5.06	22	-91	-444	-44	140	89
Net Cash From Continuing Investing Activities	-5.06	22	-91	-444	-44	140	89
Purchase of Property, Plant & Equipment	-2.89	-1.78	-6.56	-15	-16	-13	-13
Acquisitions	-1.01	-0.58	-6.86	-17	-60	-28	-30
Purchase of Investments	-	0.00	0.00	-458	-115	-12	-60
Divestitures	0.00	26	-1.34	0.50	2.19	0.00	0.00
Sale and/or Maturity of Investments	-	2.06	7.10	53	164	207	194
Other Investing Activities, net	-1.15	-3.85	-83	-6.51	-20	-14	-2.00
Net Cash From Financing Activities	176	25	1,154	28	-193	-2.58	-2.99
Net Cash From Continuing Financing Activities	176	25	1,154	28	-193	-2.58	-2.99
Repayment of Debt	-3.59	-3.04	-135	-5.00	-5.00	-3.75	0.00
Repurchase of Common Equity	0.00	-6.74	0.00	0.00	-200	0.00	0.00
Issuance of Common Equity	180	34	1,189	33	12	1.17	-2.99

This table details how cash moves in and out of Agilon Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-23	-64	4.22	-2.21	37	40	-55	33	0.27	2.03	38
Net Cash From Operating Activities	-13	-61	-48	-19	-7.70	16	-32	-35	-18	-21	24
Net Cash From Continuing Operating Activities	-13	-61	-48	-19	-7.70	16	-32	-35	-18	-21	24
Net Income / (Loss) Continuing Operations	-31	-230	-6.03	-31	-118	-106	12	-104	-110	-189	49
Consolidated Net Income / (Loss)	-31	-230	-6.03	-31	-118	-106	12	-104	-110	-189	49
Depreciation Expense	5.31	5.15	5.84	5.91	6.22	6.49	6.88	7.32	7.43	6.97	6.79
Non-Cash Adjustments To Reconcile Net Income	6.89	69	16	10	12	9.95	-12	9.09	-8.10	79	-24
Changes in Operating Assets and Liabilities, net	6.27	96	-63	-3.98	92	106	-39	53	93	83	-8.43
Net Cash From Investing Activities	-11	-2.20	51	18	47	24	-23	70	19	23	19
Net Cash From Continuing Investing Activities	-11	-2.20	51	18	47	24	-23	70	19	23	19
Purchase of Property, Plant & Equipment	-4.09	-3.93	-3.14	-3.31	-3.53	-3.27	-3.85	-3.25	-3.18	-2.97	-3.10
Acquisitions	-1.81	-12	-11	-6.46	-0.98	-9.16	-7.03	-2.68	-13	-6.79	-0.03
Purchase of Investments	-41	-7.64	0.00	-12	-	-	-48	-13	-	-	0.00
Sale and/or Maturity of Investments	37	30	75	41	51	40	35	90	35	33	22
Net Cash From Financing Activities	1.41	-0.85	0.56	-1.71	-1.41	-0.02	-0.16	-2.58	-0.24	-0.02	-5.15
Net Cash From Continuing Financing Activities	1.41	-0.85	0.56	-1.71	-1.41	-0.02	-0.16	-2.58	-0.24	-0.02	-5.15
Repayment of Debt	-1.25	-1.25	-1.25	-1.25	-1.25	-	0.00	-	-	-	-5.11
Issuance of Common Equity	2.66	0.41	1.81	-0.46	-0.16	-0.02	-0.16	-2.58	-0.24	-0.02	-0.04

This table presents Agilon Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	446	1,586	1,697	1,741	1,734	1,271
Total Current Assets	294	1,367	1,451	1,480	1,458	1,097
Cash & Equivalents	107	1,040	465	108	188	174
Restricted Cash	-	15	11	6.76	5.63	0.00
Short-Term Investments	-	0.00	412	381	212	111
Accounts Receivable	145	293	492	942	1,017	674
Prepaid Expenses	9.64	19	32	43	35	138
Plant, Property, & Equipment, net	6.46	9.16	20	28	28	25
Total Noncurrent Assets	146	210	226	233	248	149
Intangible Assets	60	55	18	64	73	66
Other Noncurrent Operating Assets	44	113	106	145	151	83
Total Liabilities & Shareholders' Equity	446	1,586	1,697	1,741	1,734	1,271
Total Liabilities	422	495	657	1,080	1,263	1,145
Total Current Liabilities	267	357	535	977	1,152	1,076
Short-Term Debt	3.04	5.00	5.00	-	0.00	19
Accounts Payable	97	113	177	239	220	127
Other Current Liabilities	163	239	301	738	932	930
Total Noncurrent Liabilities	155	138	122	103	111	68
Long-Term Debt	65	43	38	32	35	16
Other Noncurrent Operating Liabilities	90	94	82	70	76	52
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-285	1,092	1,041	661	471	127
Total Preferred & Common Equity	-285	1,092	1,041	662	471	127
Total Common Equity	-285	1,092	1,041	662	471	127
Common Stock	266	2,050	2,111	1,991	2,058	2,104
Retained Earnings	-551	-958	-1,064	-1,327	-1,587	-1,978
Accumulated Other Comprehensive Income / (Loss)	-	0.00	-5.56	-2.30	-0.09	0.92

This table presents Agilon Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	1,870	2,170	2,353	2,278	2,316	2,163	2,091	1,933	1,713	1,596	1,505
Total Current Assets	1,634	1,876	2,045	1,957	2,037	1,884	1,812	1,651	1,453	1,338	1,321
Cash & Equivalents	551	394	191	168	112	109	148	137	171	172	140
Restricted Cash	-	10	10	10	6.84	6.85	5.63	1.68	0.00	0.00	72
Short-Term Investments	408	422	389	396	307	292	245	230	156	139	91
Accounts Receivable	638	1,005	1,417	1,346	1,571	1,437	1,368	1,240	1,047	947	900
Prepaid Expenses	24	45	38	37	40	39	45	42	78	80	118
Plant, Property, & Equipment, net	18	22	24	26	28	28	28	28	27	26	25
Total Noncurrent Assets	218	272	284	295	252	251	251	254	233	232	159
Intangible Assets	61	93	94	93	72	75	73	68	66	75	62
Other Noncurrent Operating Assets	116	117	127	140	156	153	154	162	143	133	96
Total Liabilities & Shareholders' Equity	1,870	2,170	2,353	2,278	2,316	2,163	2,091	1,933	1,713	1,596	1,505
Total Liabilities	785	1,088	1,473	1,406	1,628	1,487	1,517	1,433	1,304	1,290	1,324
Total Current Liabilities	658	973	1,362	1,301	1,527	1,387	1,409	1,375	1,249	1,240	1,272
Short-Term Debt	5.00	5.00	5.00	5.00	7.50	8.75	-	35	35	35	15
Accounts Payable	162	222	258	291	252	281	218	227	172	146	202
Other Current Liabilities	491	746	1,100	1,006	1,267	1,098	1,191	1,113	1,042	1,059	1,055
Total Noncurrent Liabilities	127	116	111	105	101	100	107	58	55	50	51
Long-Term Debt	40	37	36	35	30	27	35	0.00	0.00	0.00	15
Other Noncurrent Operating Liabilities	87	79	75	70	71	73	72	58	55	50	36
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,085	1,082	879	872	688	676	575	500	409	306	181
Total Preferred & Common Equity	1,086	1,083	880	872	689	677	575	500	409	306	181
Total Common Equity	1,086	1,083	880	872	689	677	575	500	409	306	181
Common Stock	2,099	2,134	1,951	1,975	2,025	2,043	2,056	2,075	2,087	2,095	2,110
Retained Earnings	-1,008	-1,048	-1,065	-1,096	-1,333	-1,364	-1,481	-1,575	-1,679	-1,789	-1,929
Accumulated Other Comprehensive Income / (Loss)	-5.10	-3.55	-6.37	-6.23	-2.75	-2.45	0.30	0.54	0.79	0.88	0.48

This table displays calculated financial ratios and metrics derived from Agilon Health's official financial filings.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	-	-	-	-	-	-	414,581,604.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	414,581,604.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-0.94
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	0.00%	53.36%	24.88%	56.97%	80.74%	40.41%	-2.11%
EBITDA Growth	0.00%	37.53%	-786.07%	76.61%	-121.49%	-26.64%	-57.40%
EBIT Growth	0.00%	48.68%	-582.67%	73.81%	-110.82%	-26.11%	-53.55%
NOPAT Growth	0.00%	46.82%	-556.82%	71.69%	-120.29%	-25.85%	-58.57%
Net Income Growth	0.00%	78.76%	-577.39%	73.73%	-145.92%	1.03%	-50.46%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	0.00%	48.77%	-178.47%	11.71%	-19.41%	63.01%	-83.05%
Free Cash Flow Firm Growth	0.00%	0.00%	-1,392.04%	72.71%	-154.39%	57.52%	5.57%
Invested Capital Growth	0.00%	0.00%	650.88%	29.12%	80.24%	-49.42%	-223.10%
Revenue Q/Q Growth	0.00%	0.00%	-10.06%	57.55%	0.77%	8.34%	0.80%
EBITDA Q/Q Growth	0.00%	0.00%	2.40%	21.89%	-204.28%	19.86%	-16.47%
EBIT Q/Q Growth	0.00%	0.00%	2.33%	19.20%	-157.18%	17.97%	-15.26%
NOPAT Q/Q Growth	0.00%	0.00%	3.52%	12.14%	-192.23%	16.13%	-22.71%
Net Income Q/Q Growth	0.00%	0.00%	-8.69%	0.18%	-195.72%	32.41%	-26.96%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-31.58%	-0.82%	-7.73%	57.32%	-53.71%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	43.20%	-13.03%	9.78%	-20.83%
Invested Capital Q/Q Growth	0.00%	0.00%	4.94%	-35.58%	-41.17%	-52.53%	-508.82%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	4.32%	4.66%	100.00%	0.08%	-2.70%
EBITDA Margin	-8.08%	-3.29%	-23.36%	-3.48%	-4.27%	-3.85%	-6.19%
Operating Margin	-13.42%	-4.65%	-24.47%	-4.41%	-5.38%	-4.82%	-7.81%
EBIT Margin	-13.30%	-4.45%	-24.32%	-4.06%	-4.73%	-4.25%	-6.67%
Profit (Net Income) Margin	-35.59%	-4.93%	-26.74%	-4.47%	-6.09%	-4.29%	-6.60%
Tax Burden Percent	246.53%	96.33%	106.22%	117.86%	135.14%	104.53%	96.85%
Interest Burden Percent	108.59%	115.01%	103.49%	93.56%	95.19%	96.58%	102.14%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-747.53%	-75.60%	-105.45%	-137.02%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-719.59%	-72.18%	-91.05%	-123.67%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	674.65%	65.57%	74.56%	91.06%	0.00%
Return on Equity (ROE)	0.00%	-242.44%	-72.88%	-10.02%	-30.89%	-45.96%	-130.95%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-424.07%	-101.01%	-162.71%	-71.38%	0.00%
Operating Return on Assets (OROA)	0.00%	-12.14%	-36.41%	-5.90%	-11.88%	-14.83%	-26.33%
Return on Assets (ROA)	0.00%	-13.45%	-40.03%	-6.51%	-15.29%	-14.97%	-26.04%
Return on Common Equity (ROCE)	0.00%	2,786.82%	-52.69%	-10.03%	-30.91%	-45.99%	-130.95%
Return on Equity Simple (ROE_SIMPLE)	0.00%	21.09%	-37.26%	-10.26%	-39.71%	-55.23%	0.00%
Net Operating Profit after Tax (NOPAT)	-75	-40	-261	-74	-162	-204	-324
NOPAT Margin	-9.39%	-3.26%	-17.13%	-3.09%	-3.76%	-3.37%	-5.47%
Net Nonoperating Expense Percent (NNEP)	0.00%	-101.32%	-27.94%	-3.42%	-14.40%	-13.34%	-21.61%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-6.80%	-23.44%	-40.42%	-200.51%
Cost of Revenue to Revenue	0.00%	0.00%	95.68%	95.34%	0.00%	99.92%	102.70%
SG&A Expenses to Revenue	15.46%	11.27%	28.10%	8.70%	6.62%	4.44%	4.02%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	113.42%	104.65%	28.79%	9.08%	105.38%	4.90%	5.11%
Earnings before Interest and Taxes (EBIT)	-106	-54	-370	-97	-204	-258	-396
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-64	-40	-355	-83	-184	-233	-367
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	9.73	6.38	7.70	1.66	2.25
Price to Tangible Book Value (P/TBV)	0.00	0.00	10.68	6.52	8.88	2.09	4.68
Price to Revenue (P/Rev)	1.35	0.88	6.99	2.78	1.18	0.13	0.05
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	112.96	52.76	23.37	4.11	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	1.10	6.32	2.43	1.07	0.07	0.01
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.00	2.73	0.04	0.04	0.05	0.07	0.28
Long-Term Debt to Equity	0.00	2.61	0.04	0.04	0.05	0.07	0.12
Financial Leverage	0.00	-1.62	-0.94	-0.91	-0.82	-0.74	-1.04
Leverage Ratio	0.00	18.02	1.82	1.54	2.02	3.07	5.03
Compound Leverage Factor	0.00	20.72	1.88	1.44	1.92	2.96	5.14
Debt to Total Capital	0.00%	73.21%	4.25%	4.01%	4.66%	6.90%	21.63%
Short-Term Debt to Total Capital	0.00%	3.29%	0.44%	0.46%	0.00%	0.00%	11.90%
Long-Term Debt to Total Capital	0.00%	69.93%	3.81%	3.55%	4.66%	6.90%	9.74%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	334.68%	-0.03%	-0.06%	-0.12%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-307.90%	95.78%	96.05%	95.46%	93.10%	78.37%
Debt to EBITDA	0.00	-1.69	-0.14	-0.52	-0.18	-0.15	-0.10
Net Debt to EBITDA	0.00	0.97	2.83	10.16	2.51	1.59	0.68
Long-Term Debt to EBITDA	0.00	-1.61	-0.12	-0.46	-0.18	-0.15	-0.04
Debt to NOPAT	0.00	-1.71	-0.19	-0.59	-0.20	-0.17	-0.11
Net Debt to NOPAT	0.00	0.99	3.86	11.45	2.85	1.81	0.77
Long-Term Debt to NOPAT	0.00	-1.63	-0.17	-0.52	-0.20	-0.17	-0.05
Altman Z-Score	0.00	2.20	13.00	7.06	4.20	2.31	1.63
Noncontrolling Interest Sharing Ratio	0.00%	1,249.50%	27.70%	-0.04%	-0.08%	-0.07%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	0.00	1.10	3.83	2.71	1.51	1.27	1.02
Quick Ratio	0.00	0.94	3.74	2.56	1.46	1.23	0.89
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-24	-361	-99	-251	-107	-101
Operating Cash Flow to CapEx	-3,591.32%	-2,997.41%	-2,257.15%	-847.97%	-986.73%	-436.02%	-798.69%
Free Cash Flow to Firm to Interest Expense	0.00	-2.98	-58.77	-21.98	-37.66	-17.25	-15.15
Operating Cash Flow to Interest Expense	-11.45	-6.54	-24.11	-29.17	-23.46	-9.35	-15.93
Operating Cash Flow Less CapEx to Interest Expense	-11.77	-6.76	-25.17	-32.61	-25.84	-11.50	-17.92
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.00	2.73	1.50	1.45	2.51	3.49	3.95
Accounts Receivable Turnover	0.00	8.43	6.95	6.08	6.02	6.19	7.02
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	188.71	194.85	164.15	181.69	217.44	221.42
Accounts Payable Turnover	0.00	0.00	13.85	15.68	0.00	26.34	35.03
Days Sales Outstanding (DSO)	0.00	43.31	52.53	60.05	60.67	59.01	52.01
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	26.35	23.27	0.00	13.86	10.42
Cash Conversion Cycle (CCC)	0.00	43.31	26.18	36.77	60.67	45.15	41.60
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	0.00	-15	85	110	198	100	-123
Invested Capital Turnover	0.00	-157.59	43.65	24.48	28.01	40.61	-512.29
Increase / (Decrease) in Invested Capital	0.00	-15	101	25	88	-98	-224
Enterprise Value (EV)	0.00	1,342	9,622	5,802	4,632	412	35
Market Capitalization	1,072	1,072	10,629	6,647	5,096	783	286
Book Value per Share	$0.00	($0.88)	$2.77	$2.53	$1.63	$1.14	$0.31
Tangible Book Value per Share	$0.00	($1.20)	$2.53	$2.48	$1.41	$0.91	$0.15
Total Capital	0.00	92	1,140	1,084	693	506	162
Total Debt	0.00	68	48	43	32	35	35
Total Long-Term Debt	0.00	65	43	38	32	35	16
Net Debt	0.00	-39	-1,006	-844	-463	-371	-250
Capital Expenditures (CapEx)	2.89	1.78	6.56	15	16	13	13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-76	-40	33	7.82	-100	-246
Debt-free Net Working Capital (DFNWC)	0.00	30	1,015	921	503	306	39
Net Working Capital (NWC)	0.00	27	1,010	916	503	306	20
Net Nonoperating Expense (NNE)	208	20	146	33	100	56	67
Net Nonoperating Obligations (NNO)	0.00	-40	-1,006	-931	-463	-371	-250
Total Depreciation and Amortization (D&A)	41	14	15	14	20	24	29
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-6.27%	-2.60%	1.40%	0.18%	-1.65%	-4.14%
Debt-free Net Working Capital to Revenue	0.00%	2.50%	66.73%	38.57%	11.65%	5.05%	0.67%
Net Working Capital to Revenue	0.00%	2.25%	66.40%	38.36%	11.65%	5.05%	0.34%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	401.18M	408.15M	408.92M	410.97M	413.97M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	401.18M	408.15M	408.92M	410.97M	413.97M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	372.93M	413.12M	409.54M	412.30M	414.87M
Normalized Net Operating Profit after Tax (NOPAT)	-75	-40	-261	-74	-162	-202	-299
Normalized NOPAT Margin	-9.39%	-3.26%	-17.13%	-3.09%	-3.76%	-3.33%	-5.04%
Pre Tax Income Margin	-14.44%	-5.12%	-25.17%	-3.80%	-4.51%	-4.11%	-6.81%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	-11.65	-6.66	-60.21	-21.61	-30.68	-41.71	-59.57
NOPAT to Interest Expense	-8.23	-4.88	-42.40	-16.45	-24.41	-33.11	-48.83
EBIT Less CapEx to Interest Expense	-11.97	-6.88	-61.28	-25.05	-33.06	-43.85	-61.57
NOPAT Less CapEx to Interest Expense	-8.55	-5.09	-43.46	-19.89	-26.78	-35.25	-50.82
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	-0.11%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.11%	-11.23%	0.00%	0.00%	-76.10%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Agilon Health's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	413,951,779.00	414,423,149.00	414,581,604.00	414,869,759.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	413,951,779.00	414,423,149.00	414,581,604.00	16,594,790.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-0.25	-0.27	-0.46	2.95
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	63.61%	3.21%	52.17%	38.69%	27.63%	44.16%	-4.46%	-5.92%	-1.08%	3.09%	-7.33%
EBITDA Growth	-34.85%	-1,871.85%	-63.53%	-99.30%	-289.44%	38.10%	-231.04%	-209.33%	-2.85%	-55.28%	548.84%
EBIT Growth	-37.52%	-1,252.13%	-115.48%	-76.05%	-246.75%	35.99%	-899.14%	-180.88%	-3.73%	-52.17%	255.83%
NOPAT Growth	-33.12%	-1,066.50%	-1,577.59%	-49.68%	-239.77%	34.21%	-106.79%	-167.69%	1.67%	-79.30%	125.80%
Net Income Growth	-2.42%	-307.58%	-137.81%	-82.57%	-273.58%	54.10%	300.73%	-240.39%	6.30%	-78.54%	303.86%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	303.86%
Operating Cash Flow Growth	-591.80%	-22.43%	21.44%	11.73%	40.83%	126.84%	33.05%	-87.45%	-135.67%	-225.08%	174.18%
Free Cash Flow Firm Growth	-75.78%	-486.45%	93.62%	97.58%	116.67%	110.97%	1,257.92%	2,666.19%	175.88%	294.66%	121.94%
Invested Capital Growth	97.37%	80.24%	0.91%	-7.94%	-37.32%	-49.42%	-44.51%	-61.56%	-85.71%	-223.10%	-155.00%
Revenue Q/Q Growth	6.34%	-7.11%	64.17%	-7.58%	-2.15%	4.93%	0.68%	-8.99%	2.89%	9.35%	-9.50%
EBITDA Q/Q Growth	-74.63%	-431.19%	103.20%	-815.14%	-241.24%	15.57%	93.64%	-1,588.08%	-13.46%	-27.46%	118.38%
EBIT Q/Q Growth	-54.87%	-363.11%	99.13%	-2,894.01%	-205.03%	14.51%	87.20%	-741.68%	-12.65%	-25.41%	113.10%
NOPAT Q/Q Growth	-35.70%	-318.13%	93.08%	-305.38%	-208.02%	19.03%	79.55%	-424.77%	-13.14%	-47.65%	102.94%
Net Income Q/Q Growth	-87.45%	-632.09%	97.38%	-408.15%	-283.59%	10.05%	111.45%	-961.71%	-5.59%	-71.39%	125.90%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	38.61%	-369.86%	21.89%	60.82%	58.84%	313.15%	-294.82%	-9.69%	48.26%	-13.13%	215.54%
Free Cash Flow Firm Q/Q Growth	-13.67%	-4.91%	94.97%	59.50%	882.58%	-30.97%	429.29%	-10.25%	-15.87%	-1.25%	197.65%
Invested Capital Q/Q Growth	2.04%	-41.17%	46.67%	1.37%	-30.53%	-52.53%	65.98%	-29.77%	-74.17%	-508.82%	25.84%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	3.24%	300.23%	100.00%	2.17%	-4.42%	-102.96%	3.31%	-3.76%	100.00%	-101.54%	4.58%
EBITDA Margin	-2.51%	-14.37%	0.28%	-2.20%	-7.67%	-6.17%	-0.39%	-7.23%	-7.97%	-9.29%	1.89%
Operating Margin	-3.46%	-15.56%	-0.45%	-2.92%	-9.20%	-7.10%	-1.44%	-8.32%	-9.15%	-12.35%	0.28%
EBIT Margin	-2.98%	-14.85%	-0.08%	-2.60%	-8.09%	-6.59%	-0.84%	-7.75%	-8.49%	-9.74%	1.41%
Profit (Net Income) Margin	-2.77%	-21.82%	-0.38%	-2.07%	-8.11%	-6.95%	0.79%	-7.48%	-7.68%	-12.03%	3.44%
Tax Burden Percent	151.15%	138.12%	-193.77%	101.38%	100.51%	101.07%	-715.84%	100.06%	99.70%	100.71%	163.36%
Interest Burden Percent	61.50%	106.38%	-242.15%	78.55%	99.64%	104.25%	13.17%	96.45%	90.73%	122.76%	149.56%
Effective Tax Rate	0.00%	0.00%	-4.27%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.09%
Return on Invested Capital (ROIC)	-40.83%	-305.03%	-7.60%	-34.07%	-131.47%	-201.83%	-25.94%	-163.26%	-312.20%	0.00%	43.70%
ROIC Less NNEP Spread (ROIC-NNEP)	-40.28%	-288.46%	-7.85%	-34.00%	-126.09%	-194.60%	-33.57%	-156.29%	-306.47%	0.00%	28.90%
Return on Net Nonoperating Assets (RNNOA)	29.83%	236.21%	5.20%	20.13%	78.30%	143.29%	20.40%	95.65%	222.49%	0.00%	-25.72%
Return on Equity (ROE)	-11.00%	-68.82%	-2.40%	-13.93%	-53.16%	-58.54%	-5.53%	-67.61%	-89.70%	-130.95%	17.98%
Cash Return on Invested Capital (CROIC)	-87.39%	-162.71%	-57.11%	-47.83%	-43.08%	-71.38%	-34.93%	-37.39%	-68.97%	0.00%	0.00%
Operating Return on Assets (OROA)	-6.15%	-37.29%	-0.17%	-6.07%	-20.73%	-23.00%	-2.36%	-23.61%	-27.09%	-38.43%	4.77%
Return on Assets (ROA)	-5.72%	-54.80%	-0.82%	-4.84%	-20.76%	-24.24%	2.23%	-22.78%	-24.51%	-47.51%	11.66%
Return on Common Equity (ROCE)	-11.01%	-68.88%	-2.40%	-13.95%	-53.19%	-58.58%	-5.54%	-67.66%	-89.70%	-130.95%	17.98%
Return on Equity Simple (ROE_SIMPLE)	-10.19%	0.00%	-41.32%	-44.14%	-66.94%	0.00%	-48.37%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-28	-115	-7.48	-30	-93	-76	-15	-81	-92	-136	3.99
NOPAT Margin	-2.42%	-10.89%	-0.47%	-2.05%	-6.44%	-4.97%	-1.01%	-5.82%	-6.40%	-8.64%	0.28%
Net Nonoperating Expense Percent (NNEP)	-0.55%	-16.57%	0.25%	-0.07%	-5.38%	-7.23%	7.64%	-6.97%	-5.73%	-17.14%	14.81%
Return On Investment Capital (ROIC_SIMPLE)	-	-16.59%	-	-	-	-14.96%	-2.89%	-18.30%	-26.94%	-83.90%	1.89%
Cost of Revenue to Revenue	96.76%	-200.23%	0.00%	97.83%	104.42%	202.96%	96.69%	103.76%	0.00%	201.54%	95.42%
SG&A Expenses to Revenue	6.34%	6.13%	4.76%	4.69%	4.35%	3.92%	4.30%	4.03%	3.92%	3.83%	3.82%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	6.70%	315.79%	100.45%	5.09%	4.78%	-95.86%	4.75%	4.56%	109.15%	-89.19%	4.30%
Earnings before Interest and Taxes (EBIT)	-34	-157	-1.29	-39	-117	-100	-13	-108	-122	-153	20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-29	-152	4.56	-33	-111	-94	-5.97	-101	-114	-146	27
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	8.26	7.70	3.59	3.98	2.81	1.66	3.57	2.33	1.39	2.25	0.72
Price to Tangible Book Value (P/TBV)	10.04	8.88	4.18	4.66	3.39	2.09	4.38	2.98	2.07	4.68	1.10
Price to Revenue (P/Rev)	1.68	1.18	0.51	0.51	0.29	0.13	0.30	0.16	0.07	0.05	0.02
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	19.78	23.37	6.96	7.62	5.93	4.11	8.72	5.65	5.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	1.56	1.07	0.43	0.44	0.22	0.07	0.24	0.11	0.03	0.01	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.05	0.05	0.05	0.05	0.06	0.07	0.07	0.09	0.11	0.28	0.17
Long-Term Debt to Equity	0.04	0.05	0.04	0.04	0.06	0.07	0.00	0.00	0.00	0.12	0.08
Financial Leverage	-0.74	-0.82	-0.66	-0.59	-0.62	-0.74	-0.61	-0.61	-0.73	-1.04	-0.89
Leverage Ratio	2.12	2.02	2.53	2.90	3.02	3.07	3.57	3.57	4.19	5.03	5.04
Compound Leverage Factor	1.30	2.15	-6.14	2.28	3.01	3.20	0.47	3.45	3.80	6.17	7.54
Debt to Total Capital	4.36%	4.66%	5.14%	5.07%	5.72%	6.90%	6.53%	7.87%	10.25%	21.63%	14.20%
Short-Term Debt to Total Capital	0.55%	0.00%	1.03%	1.23%	0.00%	0.00%	6.53%	7.87%	10.25%	11.90%	6.97%
Long-Term Debt to Total Capital	3.82%	4.66%	4.11%	3.84%	5.72%	6.90%	0.00%	0.00%	0.00%	9.74%	7.23%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-0.08%	-0.12%	-0.11%	-0.11%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	95.72%	95.46%	94.96%	95.04%	94.28%	93.10%	93.47%	92.13%	89.75%	78.37%	85.80%
Debt to EBITDA	-0.66	-0.18	-0.19	-0.17	-0.12	-0.15	-0.14	-0.11	-0.11	-0.10	-0.09
Net Debt to EBITDA	8.84	2.51	2.02	1.79	1.25	1.59	1.37	0.94	0.88	0.68	0.82
Long-Term Debt to EBITDA	-0.57	-0.18	-0.16	-0.13	-0.12	-0.15	0.00	0.00	0.00	-0.04	-0.05
Debt to NOPAT	-0.72	-0.20	-0.22	-0.20	-0.14	-0.17	-0.16	-0.13	-0.13	-0.11	-0.10
Net Debt to NOPAT	9.62	2.85	2.32	2.09	1.49	1.81	1.55	1.10	1.04	0.77	0.89
Long-Term Debt to NOPAT	-0.63	-0.20	-0.18	-0.15	-0.14	-0.17	0.00	0.00	0.00	-0.05	-0.05
Altman Z-Score	4.57	4.29	2.47	2.86	2.37	2.61	2.85	2.45	2.14	2.26	2.21
Noncontrolling Interest Sharing Ratio	-0.07%	-0.08%	-0.08%	-0.10%	-0.05%	-0.07%	-0.07%	-0.07%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.50	1.51	1.33	1.36	1.29	1.27	1.20	1.16	1.08	1.02	1.04
Quick Ratio	1.47	1.46	1.30	1.33	1.25	1.23	1.17	1.10	1.01	0.89	0.89
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-194	-203	-10	-4.13	32	22	118	106	89	88	262
Operating Cash Flow to CapEx	-318.52%	-1,555.60%	-1,522.01%	-565.13%	-217.97%	502.73%	-831.05%	-1,079.54%	-571.78%	-691.95%	765.17%
Free Cash Flow to Firm to Interest Expense	-119.82	-101.99	-7.94	-2.43	19.92	14.17	77.90	67.38	48.49	51.28	144.64
Operating Cash Flow to Interest Expense	-8.05	-30.69	-37.21	-11.03	-4.75	10.43	-21.11	-22.32	-9.88	-11.97	13.10
Operating Cash Flow Less CapEx to Interest Expense	-10.58	-32.66	-39.65	-12.98	-6.93	8.36	-23.65	-24.39	-11.60	-13.70	11.39
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	2.07	2.51	2.17	2.34	2.56	3.49	2.82	3.04	3.19	3.95	3.39
Accounts Receivable Turnover	4.32	6.02	3.78	3.70	4.12	6.19	4.26	4.75	5.08	7.02	5.44
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	194.07	181.69	195.95	202.19	205.68	217.44	215.33	213.69	216.61	221.42	219.74
Accounts Payable Turnover	6.38	0.00	0.00	1.62	3.34	26.34	25.08	26.53	33.00	35.03	34.71
Days Sales Outstanding (DSO)	84.50	60.67	96.61	98.65	88.54	59.01	85.65	76.83	71.80	52.01	67.08
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	57.18	0.00	0.00	225.47	109.15	13.86	14.55	13.76	11.06	10.42	10.52
Cash Conversion Cycle (CCC)	27.32	60.67	96.61	-126.82	-20.61	45.15	71.10	63.07	60.74	41.60	56.57
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	337	198	300	304	211	100	166	117	30	-123	-92
Invested Capital Turnover	16.87	28.01	16.30	16.65	20.41	40.61	25.69	28.04	48.76	-512.29	155.46
Increase / (Decrease) in Invested Capital	166	88	2.71	-26	-126	-98	-133	-187	-181	-224	-258
Enterprise Value (EV)	6,666	4,632	2,087	2,317	1,253	412	1,451	660	151	35	-142
Market Capitalization	7,201	5,096	2,477	2,690	1,617	783	1,785	952	427	286	131
Book Value per Share	$2.15	$1.63	$1.69	$1.65	$1.40	$1.14	$1.21	$0.99	$0.74	$0.31	$0.44
Tangible Book Value per Share	$1.77	$1.41	$1.45	$1.40	$1.16	$0.91	$0.99	$0.77	$0.50	$0.15	$0.29
Total Capital	911	693	726	712	610	506	535	444	341	162	211
Total Debt	40	32	37	36	35	35	35	35	35	35	30
Total Long-Term Debt	35	32	30	27	35	35	0.00	0.00	0.00	16	15
Net Debt	-535	-463	-389	-372	-364	-371	-334	-292	-276	-250	-273
Capital Expenditures (CapEx)	4.09	3.93	3.14	3.31	3.53	3.27	3.85	3.25	3.18	2.97	3.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)	86	7.82	92	97	4.05	-100	-58	-88	-178	-246	-239
Debt-free Net Working Capital (DFNWC)	660	503	518	505	403	306	311	239	133	39	64
Net Working Capital (NWC)	655	503	510	497	403	306	276	204	98	20	49
Net Nonoperating Expense (NNE)	3.98	115	-1.45	0.32	24	30	-28	23	18	53	-45
Net Nonoperating Obligations (NNO)	-535	-463	-389	-372	-364	-371	-334	-292	-276	-250	-273
Total Depreciation and Amortization (D&A)	5.31	5.15	5.84	5.91	6.22	6.49	6.88	7.32	7.43	6.97	6.79
Debt-free, Cash-free Net Working Capital to Revenue	2.01%	0.18%	1.89%	1.85%	0.07%	-1.65%	-0.97%	-1.50%	-3.02%	-4.14%	-4.11%
Debt-free Net Working Capital to Revenue	15.42%	11.65%	10.64%	9.57%	7.20%	5.05%	5.19%	4.04%	2.26%	0.67%	1.09%
Net Working Capital to Revenue	15.30%	11.65%	10.48%	9.41%	7.20%	5.05%	4.61%	3.45%	1.67%	0.34%	0.84%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$2.95
Adjusted Weighted Average Basic Shares Outstanding	405.79M	408.92M	408.94M	411.27M	411.59M	410.97M	412.94M	413.84M	414.47M	413.97M	16.60M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$2.94
Adjusted Weighted Average Diluted Shares Outstanding	405.79M	408.92M	413.44M	411.27M	411.59M	410.97M	412.94M	413.84M	414.47M	413.97M	16.66M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	406.04M	409.54M	411.26M	411.48M	412.02M	412.30M	413.95M	414.42M	414.58M	414.87M	16.68M
Normalized Net Operating Profit after Tax (NOPAT)	-28	-115	-5.02	-30	-93	-76	-15	-81	-92	-136	3.99
Normalized NOPAT Margin	-2.42%	-10.89%	-0.31%	-2.05%	-6.44%	-4.97%	-1.01%	-5.82%	-6.40%	-8.64%	0.28%
Pre Tax Income Margin	-1.83%	-15.80%	0.19%	-2.04%	-8.07%	-6.88%	-0.11%	-7.48%	-7.70%	-11.95%	2.11%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-20.95	-78.71	-1.00	-22.69	-72.41	-63.79	-8.48	-68.80	-66.29	-89.04	11.06
NOPAT to Interest Expense	-17.01	-57.71	-5.83	-17.88	-57.62	-48.08	-10.22	-51.67	-50.00	-79.07	2.21
EBIT Less CapEx to Interest Expense	-23.47	-80.68	-3.45	-24.64	-74.59	-65.86	-11.02	-70.86	-68.01	-90.77	9.34
NOPAT Less CapEx to Interest Expense	-19.54	-59.68	-8.27	-19.83	-59.80	-50.15	-12.76	-53.73	-51.72	-80.80	0.49
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-225.05%	-76.10%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Here are the key takeaways for Agilon Health (AGL) based on the latest quarterly data (Q1–Q4 2025) and surrounding four-year context. The focus is on trends in revenue, profitability, cash flow, and balance-sheet metrics that may impact retail investors.

Liquidity stability: cash and cash equivalents stayed in the roughly $137M–$172M range through 2025 (Q1: $136.9M; Q3: $171.7M), supporting liquidity despite ongoing losses.
Low long-term debt: long-term debt remained at 0 across the latest quarters (notably Q3 2025 and Q2 2025), reducing interest burden and leverage risk.
Investing cash inflows offset some operating cash burn: net cash from continuing investing activities was positive in several quarters (Q2 2025: +$70.46M; Q3 2025: +$18.66M; Q4 2025: +$22.58M), helping offset operating outflows.
Revenue scale remains sizable but variable: operating revenue ran in the 1.43B–1.57B range across the period, with Q3 2025 showing a large gross profit and Q4 2025 showing a sharp margin deterioration.
Share count relatively stable: weighted-average shares outstanding hovered around 413–414 million (basic/diluted), indicating no dramatic equity dilution during these quarters.
Modest short-term debt: short-term debt hovered around $34.9M–$34.95M, indicating manageable near-term leverage.\n
Gross margin collapse in Q4 2025: cost of revenue severely exceeded revenue (Q4 2025) — Total Revenue about $1.57B vs. Total Cost of Revenue around $3.16B, producing a gross loss of roughly $1.59B.
Net income consistently negative in 2025: quarterly net income attributable to common shareholders was negative in all 2025 quarters, with Q4 2025 at about -$188.9M, underscoring ongoing profitability challenges.
Operating cash flow negative each quarter: net cash from operating activities was negative in 2025 (Q4 -$20.5M; Q3 -$18.2M; Q2 -$35.1M; Q1 around -$32M), indicating ongoing cash burn from core operations.
Rising accumulated deficit: retained earnings declined over 2025, moving from around -$1.33B in early 2025 to approximately -$1.79B by Q4 2025, signaling a growing equity deficit.

05/07/26 12:46 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Agilon Health's Financials

When does Agilon Health's fiscal year end?

According to the most recent income statement we have on file, Agilon Health's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has Agilon Health's net income changed over the last 6 years?

Agilon Health's net income appears to be on an upward trend, with a most recent value of -$391.35 million in 2025, rising from -$282.74 million in 2019. The previous period was -$260.10 million in 2024. See Agilon Health's forecast for analyst expectations on whatâ€™s next for the company.

What is Agilon Health's operating income?

Agilon Health's total operating income in 2025 was -$463.24 million, based on the following breakdown:

Total Gross Profit: -$160.02 million
Total Operating Expenses: $303.22 million

How has Agilon Health's revenue changed over the last 6 years?

Over the last 6 years, Agilon Health's total revenue changed from $794.41 million in 2019 to $5.93 billion in 2025, a change of 646.8%.

How much debt does Agilon Health have?

Agilon Health's total liabilities were at $1.14 billion at the end of 2025, a 9.4% decrease from 2024, and a 171.5% increase since 2020.

How much cash does Agilon Health have?

In the past 5 years, Agilon Health's cash and equivalents has ranged from $106.80 million in 2020 to $1.04 billion in 2021, and is currently $173.71 million as of their latest financial filing in 2025.

How has Agilon Health's book value per share changed over the last 6 years?

Over the last 6 years, Agilon Health's book value per share changed from 0.00 in 2019 to 0.31 in 2025, a change of 30.6%.

Related Companies

Financial statements for NYSE:AGL last updated on 5/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Agilon Health (AGL) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Agilon Health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Agilon Health (AGL) Financials

Annual Income Statements for Agilon Health

Quarterly Income Statements for Agilon Health

Annual Cash Flow Statements for Agilon Health

Quarterly Cash Flow Statements for Agilon Health

Annual Balance Sheets for Agilon Health

Quarterly Balance Sheets for Agilon Health

Annual Metrics And Ratios for Agilon Health

Quarterly Metrics And Ratios for Agilon Health

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Agilon Health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools